R&D Pipeline
R&D Pipeline (In-House)
As of July 2026
| Product name / Generic name / Development code |
Expected indications | Category | Development stage | Development classification |
|
Olutasidenib |
Relapsed / refractory acute myeloid leukemia | IDH1 inhibition | NDA |
In-licensed |
| Yselty / Linzagolix |
Endometriosis | GnRH receptor antagonist | Phase III | Kissei |
| Cretostimogene grenadenorepvec / CG0070 |
Non-muscle-invasive bladder cancer in high-risk patients | Oncolytic Viral Therapy | Phase III | In-licensed / CG Oncology (U.S.) |
| Rovatirelin / KPS-0373 |
Spinocerebellar degeneration | TRH receptor agonist | Phase III | In-licensed / Sionogi (Japan) |
| Matsupexole / KDT-3594 |
Parkinson's disease | Dopamine receptor agonist | Phase II | Kissei |
| KSP-0914 | Graves' disease | TSH receptor inhibition | Phase I | Kissei |
| KSP-0576 | Overactive bladder / interstitial cystitis and bladder pain syndrome | TRPM8 inhibition | Phase I | Kissei |
| KSP-0930 | Narcolepsy | Orexin 2 receptor agonist | Phase I | Kissei |
R&D Pipeline (Out-Licensing)
As of July 2026
| Generic name | Expected indications | Category | Countries ＆ Regions | Development company | Development stage |
| Linzagolix | Uterine fibroids | GnRH receptor antagonist | 3 countries* | Theramex (U.K.) | NDA |
| South Korea | JW Pharmaceutical (South Korea) | Phase III | |||
| Endometriosis | Taiwan | Synmosa Biopharma (Taiwan) | NDA | ||
| 3 countries* | Theramex (U.K.) | NDA | |||
| Silodosin | Dysuria associated with benign prostatic hyperplasia | Alpha 1A adrenergic receptor antagonist | Vietnam | Eisai (Japan) | NDA |
| Fostamatinib | Persistent and chronic immune thrombocytopenia | Tyrosine kinase inhibition | Taiwan | Tai Tien Pharmaceuticals (Taiwan) | NDA |
* Brazil, Republic of South Africa and Mexico
